Baillie Gifford & Co
CYTK icon

Baillie Gifford & Co’s Cytokinetics CYTK Stock Holding History

Baillie Gifford & Co’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-340
Closed -$12K – 333
2023
Q1 		$12K Hold
340
– – ﹤0.01% 384
2022
Q4 		$15.6K Hold
340
– – ﹤0.01% 367
2022
Q3 		$16K Hold
340
– – ﹤0.01% 356
2022
Q2 		$13K Buy
+340
New +$13.7K ﹤0.01% 385

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Baillie Gifford & Co's CYTK Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 340 shares — an estimated $12K sold.

Baillie Gifford & Co first reported a position in CYTK in Q2 2022 and held it in 4 quarters. The position peaked at $16K in Q3 2022. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 340 Cytokinetics shares in Q2 2023, an estimated $12K.
  • Baillie Gifford & Co first reported a position in Cytokinetics in Q2 2022 and held it in 4 quarters.
  • Baillie Gifford & Co's Cytokinetics position peaked at $16K in Q3 2022.
  • 253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.